MY140504A - Statin-mmp inhibitor combinations - Google Patents

Statin-mmp inhibitor combinations

Info

Publication number
MY140504A
MY140504A MYPI99000951A MYPI9900951A MY140504A MY 140504 A MY140504 A MY 140504A MY PI99000951 A MYPI99000951 A MY PI99000951A MY PI9900951 A MYPI9900951 A MY PI9900951A MY 140504 A MY140504 A MY 140504A
Authority
MY
Malaysia
Prior art keywords
statin
mmp inhibitor
inhibitor combinations
combinations
mmp
Prior art date
Application number
MYPI99000951A
Other languages
English (en)
Inventor
Newton Roger Schofield
Roth Bruce David
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MY140504A publication Critical patent/MY140504A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI99000951A 1998-03-17 1999-03-15 Statin-mmp inhibitor combinations MY140504A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
MY140504A true MY140504A (en) 2009-12-31

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99000951A MY140504A (en) 1998-03-17 1999-03-15 Statin-mmp inhibitor combinations

Country Status (18)

Country Link
EP (1) EP1063991A1 (enExample)
JP (1) JP2002506818A (enExample)
KR (1) KR20010041916A (enExample)
AR (1) AR018113A1 (enExample)
AU (1) AU1591699A (enExample)
BR (1) BR9815745A (enExample)
CA (1) CA2309588A1 (enExample)
CO (1) CO5070670A1 (enExample)
GT (1) GT199900039A (enExample)
HN (1) HN1999000029A (enExample)
MY (1) MY140504A (enExample)
NZ (1) NZ505994A (enExample)
PA (1) PA8469001A1 (enExample)
PE (1) PE20000348A1 (enExample)
SV (1) SV1999000026A (enExample)
UY (1) UY25436A1 (enExample)
WO (1) WO1999047138A1 (enExample)
ZA (1) ZA992106B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CA2590278A1 (en) 2004-12-15 2006-06-22 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
EP1948599A1 (en) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US20110182851A1 (en) * 2008-07-11 2011-07-28 Jan Nilsson Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284142B6 (sk) * 1995-11-02 2004-10-05 Warner-Lambert Company Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku
SK282863B6 (sk) * 1996-05-17 2002-12-03 Warner-Lambert Company Bifenylsulfonamidy, ich použitie a farmaceutické prostriedky na ich báze
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
JP2002506818A (ja) 2002-03-05
CA2309588A1 (en) 1999-09-23
KR20010041916A (ko) 2001-05-25
EP1063991A1 (en) 2001-01-03
BR9815745A (pt) 2000-11-14
GT199900039A (es) 2000-09-06
UY25436A1 (es) 2001-10-25
AU1591699A (en) 1999-10-11
PE20000348A1 (es) 2000-05-22
WO1999047138A1 (en) 1999-09-23
CO5070670A1 (es) 2001-08-28
AR018113A1 (es) 2001-10-31
NZ505994A (en) 2003-10-31
HN1999000029A (es) 1999-09-29
ZA992106B (en) 1999-09-30
PA8469001A1 (es) 2002-09-17
SV1999000026A (es) 2000-01-18

Similar Documents

Publication Publication Date Title
NL300179I2 (nl) Geneesmiddelvoorlopers van trombineremmers.
YU15299A (sh) Farmaceutski sastavi
MY125467A (en) Olanzapine dihydrate d
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
AU7031500A (en) Therapeutic quinazoline compounds
NO990760D0 (no) 1,4-heterocykliske metallproteaseinhibitorer
MXPA03010327A (es) USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.
YU34199A (sh) Primena inhibitora gastrointestinalne lipaze
EP1776954A3 (en) The use of inhibitors of the renin-angiotensin system for the treatment of stroke
AU4905097A (en) Thrombin inhibitors
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
MY118381A (en) Statin-carboxyalkylether combinations
GB9907571D0 (en) Compounds
EP0858262A4 (en) THROMBIN INHIBITORS
ZA985182B (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
NZ320259A (en) Deodorizing preparations containing cationic biopolymers, aluminium hydrochlorate and esterase inhibitors
MY140504A (en) Statin-mmp inhibitor combinations
IL139144A0 (en) Mycobacterial inhibitors
AU1103699A (en) Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
BR0112460A (pt) Método para tratamento de sépsis
EP1351680B8 (fr) Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament
AU1653100A (en) Use of diminazene-di-aceturate for treating malaria
EP1082967A4 (en) PREVENTIVE / TREATMENT PREPARATIONS FOR AUTOIMMUNE DEMYELINIZING DISEASES